Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake

NCT05009251 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45061

Last updated 2025-01-03

Study results available
· View outcomes & findings →

Summary

The study team previously demonstrated that patients are more likely to receive flu vaccine after learning that they are at high risk for flu complications. Building on this past work, the present study will explore whether providing reasons that patients are considered high risk for flu complications (a) further increases the likelihood they will receive flu vaccine and (b) decreases the likelihood that they receive diagnoses of flu and/or flu-like symptoms in the ensuing flu season. It will also examine whether informing patients that their high-risk status was determined by analyzing their medical records or by an artificial intelligence (AI) / machine-learning (ML) algorithm analyzing their medical records will affect the likelihood of receiving the flu vaccine or diagnoses of flu and/or flu-like symptoms.

Conditions

  • Influenza
  • Vaccination
  • Health Promotion
  • Health Behavior
  • Risk Reduction

Interventions

BEHAVIORAL

Algorithm-based recommendation

Mailed letter, SMS, and/or patient portal message

BEHAVIORAL

Reminder

Mailed letter, short message service (SMS) text, and/or patient portal message

BEHAVIORAL

Risk reduction

Mailed letter, SMS, and/or patient portal message

BEHAVIORAL

Medical records-based recommendation

Mailed letter, SMS, and/or patient portal message

Sponsors & Collaborators

  • Geisinger Clinic

    collaborator OTHER
  • Massachusetts Institute of Technology

    collaborator OTHER
  • National Institute on Aging (NIA)

    collaborator NIH
  • National Bureau of Economic Research, Inc.

    lead OTHER

Principal Investigators

  • Michelle N Meyer, PhD JD · Geisinger Clinic

  • Christopher F Chabris, PhD · Geisinger Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2021-11-05
Completion
2022-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05009251 on ClinicalTrials.gov